Mergers and acquisitions: Strategic moves forward or frenzies of futile activity?
New biopharmaceutical industry studies shed light on a contentious issue
mergers and acquisitions have driven the concentration process that has both shaped and shaken the biopharmaceutical industry during the past 20 years. The current edition of the Bienentanz Buzz Letter reports on the results of two recent biopharmaceutical industry studies conducted by renowned business academics that have shed new light on M&A. Extensive data was analysed to determine which companies have the tendency to merge and under which conditions those mergers are likely to prove successful in the years to follow. The online newsletter discusses the implications and refers directly to the publications, both of which are currently available for download on the internet.
The Bienentanz Buzz Letter is a life science management newsletter that gets to the core of industry-relevant issues and can be subscribed to free of charge using the Contact-button below.
Organizations
Related link
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.